Bb Biotech
Bb Biotech AG, headquartered in Switzerland (CH), is a prominent player in the biotechnology industry, specialising in the development and investment in innovative biopharmaceutical companies. Founded in 1993, Bb Biotech has established itself as a leader in the sector, focusing on areas such as drug development, therapeutic solutions, and advanced medical technologies. With a strong presence in Europe and North America, Bb Biotech is known for its strategic investments in cutting-edge biotech firms, which are dedicated to addressing unmet medical needs. The company’s unique approach combines financial acumen with deep industry expertise, enabling it to identify and nurture high-potential projects. Recognised for its significant contributions to the biotech landscape, Bb Biotech continues to enhance its market position through a robust portfolio of core products and services, driving innovation and improving patient outcomes globally.
DitchCarbon Score
How does Bb Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Financial Intermediation industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bb Biotech's score of 15 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bb Biotech's reported carbon emissions
In 2023, Bb Biotech reported total carbon emissions of approximately 801,000 kg CO2e. This figure includes 32,000 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 44,000 kg CO2e from Scope 2 emissions, which encompasses purchased heat and electricity. The majority of their emissions, about 725,000 kg CO2e, fall under Scope 3, with significant contributions from business travel (499,000 kg CO2e) and purchased goods and services (499,000 kg CO2e). In 2022, the company recorded total emissions of around 608,000 kg CO2e, with Scope 1 emissions at 10,000 kg CO2e and Scope 2 emissions at 23,000 kg CO2e. Scope 3 emissions were again the largest component, totalling approximately 575,000 kg CO2e. The 2021 emissions were reported at 617,000 kg CO2e, with Scope 1 at 21,000 kg CO2e, Scope 2 at 20,000 kg CO2e, and Scope 3 emissions reaching 576,000 kg CO2e. In 2020, Bb Biotech's total emissions were about 248,000 kg CO2e, with Scope 1 emissions at 27,000 kg CO2e and Scope 2 emissions at 28,000 kg CO2e. Scope 3 emissions accounted for the largest share at approximately 193,000 kg CO2e. Despite these figures, Bb Biotech has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further clarity on their long-term climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 27,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 28,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | 193,000 | 000,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bb Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
